Leading Companies

Global Erectile Dysfunction Treatment Market - Cross Sectional Analysis:

The key players focusing on organic growth strategies, such as product approvals for erectile dysfunction, is also expected to drive the market growth of in the North America region over the forecast period. For instance, in March 2022, Lupin Limited (Lupin) India based multinational pharmaceutical company, announced that it had received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL to market a generic equivalent of Revatio for Oral Suspension, 10 mg/mL, of Viatris Specialty LLC, a global pharmaceutical company. Sildenafil is used to treat impotence or erectile dysfunction-ED

Global Erectile Dysfunction Treatment Market: Key Developments

In January 2020, Greenstone, is part of the Upjohn business and a wholly owned subsidiary of Pfizer Inc., and Roman, an innovative digital healthcare clinic for men, announced a supply agreement to offer Roman members access to the only U.S. FDA-approved authorized generic version of Viagra (sildenafil citrate).

In December 2020, Glenmark Pharmaceuticals Ltd. an India-based multinational pharmaceutical company, received final approval from the U.S. Food and Drug Administration (FDA) for Tadalafil tablets USP in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. Tadalafil tablets are used to treat erectile dysfunction by increasing blood flow to the penis during sexual stimulation.

Global Erectile Dysfunction Treatment Market: Key Players

The major players operating in the global erectile dysfunction treatment market include Mangoceuticals, Inc, Futura Medical, CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific , Cipla Ltd , Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLC.